猪瘟标记疫苗研究进展
|
摘要
猪瘟(classical swine fever,CSF)是一种致病性强、传染性高的烈性疾病,由猪瘟病毒(classical swine fever virus,CSFV)引起并严重危害养猪业。已被世界动物卫生组织(OIE)列为必须报告的动物传染病。过去数十年,防控猪瘟的方法主要是免疫猪瘟弱毒活疫苗,但由于无法区分自然感染与疫苗免疫,研发新型、安全、高效的能将感染和免疫动物区分的标记疫苗是当前及未来猪瘟防控的目标。本文在介绍猪瘟病毒分子特征的同时,总结了已有的猪瘟疫苗以及研发中的新型猪瘟标记疫苗,给猪瘟疫苗的研发和猪瘟的防控提供借鉴。
Classical swine fever(CSF) is an acute and highly contagious disease caused by classical swine fever virus(CSFV), which causes severe damage to the swine industry. And CSF is a notifiable disease and has to be reported to the World Organisation for Animal Health(OIE). In the past few decades, the main method of preventing and controlling CSF was to immunize live attenuated vaccines. However, due to the inability to differentiate infected from vaccinated animals(DIVA), the development of new, safe and efficient marker vaccines is the target of current and future prevention and control of CSF. This paper introduced the molecular characteristics of CSFV. At the same time, it summarized the existing vaccine and the new marker vaccine being developed, and provided reference for the development of CSF vaccine and the prevention and control of CSF.
Classical swine fever(CSF) is an acute and highly contagious disease caused by classical swine fever virus(CSFV), which causes severe damage to the swine industry. And CSF is a notifiable disease and has to be reported to the World Organisation for Animal Health(OIE). In the past few decades, the main method of preventing and controlling CSF was to immunize live attenuated vaccines. However, due to the inability to differentiate infected from vaccinated animals(DIVA), the development of new, safe and efficient marker vaccines is the target of current and future prevention and control of CSF. This paper introduced the molecular characteristics of CSFV. At the same time, it summarized the existing vaccine and the new marker vaccine being developed, and provided reference for the development of CSF vaccine and the prevention and control of CSF.
引文
[1]翁善钢.猪瘟的流行史和现状[J].中国猪业,2011(3):36-37.
[2]韩焘,张宁宁,齐鲁,等.猪瘟退出强制免疫后的若干问题[J].中国动物检疫,2017, 34(5):60-63.
[3] Collett MS, Moennig V, Horzinek MG. Recent advances in pestivirus research[J]. Journal of General Virology, 1989, 70(2):253.
[4]Becher PR Avalos RR, RR,Orlich M, et al. Genetic and antigenIC characterizadoon of novel pestivirus genotypes:implications for classification[J]. Virology, 2003, 3;1(1):96-104.
[5]Thiel HJ, Stark R, Weiland E, et al. Hog cholera virus:molecular composition of virions from a pestivirus[J]. Journal ofVirology, 1991, 65(9):4705-4712.
[6] Bintintan I, Meyers G. A new type of signal peptidase cleavage site identified in an RNA virus polyprotein[J]. Journal of Biological Chemistry, 2010, 285(12):8572-8584.
[7] Li Y, Xie L, Zhang L, et al. The E2 glycoprotein is necessary but not sufficient for the adaptation of classical swine fever virus laprlized vaccine C-strain to the rabbit[J]. Virology, 2018,519:197-206.
[8] Oirschot JT. Vaccinology of classical swine fever:from lab to field[J]. Veterinary Microbiology, 2003, 96(4):367-384.
[9]Beer M, Reimann I,Hoffmann B, et al. Novel marker vaccines against classical swine fever[J]. Vaccine, 2007, 25(30):5665-5670.
[10]邹海涛,兰邹然,姜平.猪瘟标记疫苗研究现状[J].动物医学进展,2011,32(11):1,1-115.
[11] Ahrens U, Kaden V, Drexler C, et al. Efficacy of the classical swine fever(CSF)marker vaccine Porcilis Pesti in pregnant sows[J]. Veterinary Microbiology, 2000, 77(1):83-97.
[12] Toledo JR,Barrera M, Farnos O,etal. HumanαIFN coformulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs[J]. Vaccine, 2010, 28(50):7907-7914.
[13] Lin GJ, Liu TY, Yuyao T, et al. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune respons:[J]. Veterinary Microbiology, 2009, 139(3-4):369-374.
[14] Hua RH, Huo H, Li YN, et al. Generation and efficacy evaluation of recombinant classical swine fever virus E2glycoprotein expressed in stable transgenic mammalian cell line[J]. Plos One, 2014, 9(9):e106891.
[15] Madera R, Gong W, Wang L, et al. Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge[J]. BMC Veterinary Research, 2016, 12(1):197.
[16] Xu YG, Guan XT, Liu ZM, et al. Immunogenicity in swine of orally administered recombinant lactobacillus plantarum expressing classical swine fever virus E2 protein in conjunction with thymosinα-1 as an adjuvant[J]. Applied&Environmental Microbiology, 2015, 81(11):3745-3752.
[17] Suárez M, Sordo Y, Prieto Y, et al. A single dose of the novel chimeric subunit vaccine E2-CD154 confers early full protection against classical swine fever virms[J]. Vaccine, 2017,35(34):4437.
[18] Muaoz GS, Sordo Y, Pérez SM, et al. Efficacy of E2glycoprotein fused to porcine CD154 as a novel chimeric subunit vaccint to prevent classical swine fever virus vertical transmission in pregnant sows[J]. Veterinary Microbiology, 2017,274(8):110-116.
[19] Meyers G, Tautz N,Becher P, et al. Recovery of cytopathogenic and noncytopathogenic bovine viral diarrhea viruses from cDNA constructs[J]. Journal of Virology, 1996, 70(12):8606-8613.
[20] Reimann I, Depner K, Trapp S, et al. An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus[J]. Virology, 2004,322(1):143-157.
[21] Goller KV, Dr(a|¨)ger C, Hoper D, et al. Classical swine fever virus marker vaccine strain CP7_E2alf:genetic stability in vitro, and in vivo[J]. Archives of Virology, 2015, 160(12):3121-3125.
[22]Blome S, Gabriel C, Schmeiser S, et al. Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes[J].Veterinary Microbiology, 2014, 169(1-2):8-17.
[23] Lévai R, Barna T, Fábián K, et al. Pre-registration efficacy study of a novel marker vaccine against classical swine fever on maternally derived antibody negative(MDA-)target animals[J].Biologicals, 2016, 43(2):92-99.
[24] Henke J, Carlson J, Zani L, et al. Protection against transplacental transmission of moderately virulent classical swine fever virus using live marker vaccine"CP7_E2alf"[J]. Vaccine,2018, 36(29):4181-4187.
[25] Aebischer A, M(u|¨)ller M, Hofnann M A. Two newly developed Erns-based ELISAs allow the differentiation of classical Swine fever virus-infected from marker-vacinatrd animals and the discrimination of pestivirus antibodies[J]. Veterinary Microbiology, 2013, 161(3-4):274-285.
[26]Biome S,Wernike K, Reimann I, et al. A decade of re-search into classical swine fever marker vaccine CP7_E2alf(Suvaxyn~(?)CSF Marker):a review of vaccine properties[J]. Veterinary Research, 2017, 48(1):51.
[27] Voigt H, Merant C, Wienhold D, et al. Efficient priming against classical swine fever with a safe glycoprotein E2expressing Orf virus recombinant(ORFV VrV-E2)[J]. Vaccine,2007, 25(31):5915-5926.
[28]李谱华,张森涛,王养会,等.猪瘟病毒E2基因重组鸡痘病毒的构建及免疫保护试验[J].上海交通大学学报(农业科学版),2009, 27(2):96-100.
[29] Peeters B, Bienkowska SK, Hulst M, et al.Eiodogically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever[J]. Journal of General Virology, 1997(78):3311-3315.
[30]韩爽,陈晓春,邓永,等.表达猪瘟E2基因的重组伪狂犬病毒构建及其生物学特性分析[J].中国兽药杂志,2018(5):29-37.
[31]张小苗,张恒,杨玉艾,等.表达猪瘟病毒Erns-EZ基因重组腺病毒疫苗在兔体上的免疫原性分析[J].动物医学进展,2015,.36(9):8-12.
[32]孙元,祁巧芬,梁冰冰,等.表达猪瘟病毒E2蛋白的重组腺病毒的构建及其在兔体内的免疫原性分析[J].生物工程学报,2008,24(10):1734-1739.
[33]孙元,刘大飞,王宇飞,等.表达猪瘟病毒E2蛋白的重组腺病毒对猪的免疫效力评价[J].中国动物传染病学报,2009, 17(1):15-21.
[34]李河林.猪瘟病毒重组腺病毒载体疫苗的构建及免疫保护试验[D].杨凌:西北农林科技大学,2015.
[35]余兴龙,涂长春,李红卫,等.猪瘟病毒E2基因真核表达质粒的构建及基因疫苗的研究[J].中国病毒学,2000, 15(3),264-271.
[36]李娜,孙元,仇华吉.猪瘟DNA疫苗研究进展[J].生物工程学报,2010, 26(3):281-289.
[37] Li W, Mao L, Zhou B, et al. The swine CD81 enhances E2-based DNA vaccination against classical swine fever[J].Vaccine, 2015, 33(30):3542-3548.
[38]袁晋,孙元,王春花,等.腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2最早提供完全攻毒保护时间的研究[J].中国预防兽医学报,2014. 36(10):792-796.
[39]雷建林,杜明亮,孙元,等.母源抗体对腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2免疫效力的影响[J].中国预防兽医学报,2016, 38(6):484-488.
[40]秦华洋.腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2不同免疫途径的免疫效力比较[D].泰安:山东农业大学,2014.
[41]夏水利,孙元,雷建林,等.同时接种伪狂犬病活疫苗Bartha-K61株对嵌合载体猪瘟疫苗rAdV-SFV-E2免疫效力的影响[J].中国预防兽医学报,2016, 38(8)6642-645.
[42] Kosmidou A, Ahl N R, Thiel HJ, et al. Differentiation of classical swine fever virus(CSFV)strains using monoclonal antibodies against structural glycoproteins[J]. Veterinary Microbiology, 1995, 47(1-2):111.
[43] Widjojoatnodjo M, Van GH, Van RP, et al. Classical swine fever virus E(rns)deletion mutants:trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines[J]. Journal of Virology, 2000, 74(7):2973-2980.
[44] Hplinka L, Fernandez SI, Prarat M, et al. Development of a live attenuated antigenic marker classical swine fever vaccine[J]. Virology, 20093 384(1):106-113.
[45] Holinka LG, Fernandez SI, Sanford B, et al. Development of an improved live attenuated antigenic marker CSF vaccine strain candidate with an increased genetic stability[J].Virology, 2011(471-473):13-18
[2]韩焘,张宁宁,齐鲁,等.猪瘟退出强制免疫后的若干问题[J].中国动物检疫,2017, 34(5):60-63.
[3] Collett MS, Moennig V, Horzinek MG. Recent advances in pestivirus research[J]. Journal of General Virology, 1989, 70(2):253.
[4]Becher PR Avalos RR, RR,Orlich M, et al. Genetic and antigenIC characterizadoon of novel pestivirus genotypes:implications for classification[J]. Virology, 2003, 3;1(1):96-104.
[5]Thiel HJ, Stark R, Weiland E, et al. Hog cholera virus:molecular composition of virions from a pestivirus[J]. Journal ofVirology, 1991, 65(9):4705-4712.
[6] Bintintan I, Meyers G. A new type of signal peptidase cleavage site identified in an RNA virus polyprotein[J]. Journal of Biological Chemistry, 2010, 285(12):8572-8584.
[7] Li Y, Xie L, Zhang L, et al. The E2 glycoprotein is necessary but not sufficient for the adaptation of classical swine fever virus laprlized vaccine C-strain to the rabbit[J]. Virology, 2018,519:197-206.
[8] Oirschot JT. Vaccinology of classical swine fever:from lab to field[J]. Veterinary Microbiology, 2003, 96(4):367-384.
[9]Beer M, Reimann I,Hoffmann B, et al. Novel marker vaccines against classical swine fever[J]. Vaccine, 2007, 25(30):5665-5670.
[10]邹海涛,兰邹然,姜平.猪瘟标记疫苗研究现状[J].动物医学进展,2011,32(11):1,1-115.
[11] Ahrens U, Kaden V, Drexler C, et al. Efficacy of the classical swine fever(CSF)marker vaccine Porcilis Pesti in pregnant sows[J]. Veterinary Microbiology, 2000, 77(1):83-97.
[12] Toledo JR,Barrera M, Farnos O,etal. HumanαIFN coformulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs[J]. Vaccine, 2010, 28(50):7907-7914.
[13] Lin GJ, Liu TY, Yuyao T, et al. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune respons:[J]. Veterinary Microbiology, 2009, 139(3-4):369-374.
[14] Hua RH, Huo H, Li YN, et al. Generation and efficacy evaluation of recombinant classical swine fever virus E2glycoprotein expressed in stable transgenic mammalian cell line[J]. Plos One, 2014, 9(9):e106891.
[15] Madera R, Gong W, Wang L, et al. Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge[J]. BMC Veterinary Research, 2016, 12(1):197.
[16] Xu YG, Guan XT, Liu ZM, et al. Immunogenicity in swine of orally administered recombinant lactobacillus plantarum expressing classical swine fever virus E2 protein in conjunction with thymosinα-1 as an adjuvant[J]. Applied&Environmental Microbiology, 2015, 81(11):3745-3752.
[17] Suárez M, Sordo Y, Prieto Y, et al. A single dose of the novel chimeric subunit vaccine E2-CD154 confers early full protection against classical swine fever virms[J]. Vaccine, 2017,35(34):4437.
[18] Muaoz GS, Sordo Y, Pérez SM, et al. Efficacy of E2glycoprotein fused to porcine CD154 as a novel chimeric subunit vaccint to prevent classical swine fever virus vertical transmission in pregnant sows[J]. Veterinary Microbiology, 2017,274(8):110-116.
[19] Meyers G, Tautz N,Becher P, et al. Recovery of cytopathogenic and noncytopathogenic bovine viral diarrhea viruses from cDNA constructs[J]. Journal of Virology, 1996, 70(12):8606-8613.
[20] Reimann I, Depner K, Trapp S, et al. An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus[J]. Virology, 2004,322(1):143-157.
[21] Goller KV, Dr(a|¨)ger C, Hoper D, et al. Classical swine fever virus marker vaccine strain CP7_E2alf:genetic stability in vitro, and in vivo[J]. Archives of Virology, 2015, 160(12):3121-3125.
[22]Blome S, Gabriel C, Schmeiser S, et al. Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes[J].Veterinary Microbiology, 2014, 169(1-2):8-17.
[23] Lévai R, Barna T, Fábián K, et al. Pre-registration efficacy study of a novel marker vaccine against classical swine fever on maternally derived antibody negative(MDA-)target animals[J].Biologicals, 2016, 43(2):92-99.
[24] Henke J, Carlson J, Zani L, et al. Protection against transplacental transmission of moderately virulent classical swine fever virus using live marker vaccine"CP7_E2alf"[J]. Vaccine,2018, 36(29):4181-4187.
[25] Aebischer A, M(u|¨)ller M, Hofnann M A. Two newly developed Erns-based ELISAs allow the differentiation of classical Swine fever virus-infected from marker-vacinatrd animals and the discrimination of pestivirus antibodies[J]. Veterinary Microbiology, 2013, 161(3-4):274-285.
[26]Biome S,Wernike K, Reimann I, et al. A decade of re-search into classical swine fever marker vaccine CP7_E2alf(Suvaxyn~(?)CSF Marker):a review of vaccine properties[J]. Veterinary Research, 2017, 48(1):51.
[27] Voigt H, Merant C, Wienhold D, et al. Efficient priming against classical swine fever with a safe glycoprotein E2expressing Orf virus recombinant(ORFV VrV-E2)[J]. Vaccine,2007, 25(31):5915-5926.
[28]李谱华,张森涛,王养会,等.猪瘟病毒E2基因重组鸡痘病毒的构建及免疫保护试验[J].上海交通大学学报(农业科学版),2009, 27(2):96-100.
[29] Peeters B, Bienkowska SK, Hulst M, et al.Eiodogically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever[J]. Journal of General Virology, 1997(78):3311-3315.
[30]韩爽,陈晓春,邓永,等.表达猪瘟E2基因的重组伪狂犬病毒构建及其生物学特性分析[J].中国兽药杂志,2018(5):29-37.
[31]张小苗,张恒,杨玉艾,等.表达猪瘟病毒Erns-EZ基因重组腺病毒疫苗在兔体上的免疫原性分析[J].动物医学进展,2015,.36(9):8-12.
[32]孙元,祁巧芬,梁冰冰,等.表达猪瘟病毒E2蛋白的重组腺病毒的构建及其在兔体内的免疫原性分析[J].生物工程学报,2008,24(10):1734-1739.
[33]孙元,刘大飞,王宇飞,等.表达猪瘟病毒E2蛋白的重组腺病毒对猪的免疫效力评价[J].中国动物传染病学报,2009, 17(1):15-21.
[34]李河林.猪瘟病毒重组腺病毒载体疫苗的构建及免疫保护试验[D].杨凌:西北农林科技大学,2015.
[35]余兴龙,涂长春,李红卫,等.猪瘟病毒E2基因真核表达质粒的构建及基因疫苗的研究[J].中国病毒学,2000, 15(3),264-271.
[36]李娜,孙元,仇华吉.猪瘟DNA疫苗研究进展[J].生物工程学报,2010, 26(3):281-289.
[37] Li W, Mao L, Zhou B, et al. The swine CD81 enhances E2-based DNA vaccination against classical swine fever[J].Vaccine, 2015, 33(30):3542-3548.
[38]袁晋,孙元,王春花,等.腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2最早提供完全攻毒保护时间的研究[J].中国预防兽医学报,2014. 36(10):792-796.
[39]雷建林,杜明亮,孙元,等.母源抗体对腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2免疫效力的影响[J].中国预防兽医学报,2016, 38(6):484-488.
[40]秦华洋.腺病毒/甲病毒复制子嵌合载体猪瘟疫苗rAdV-SFV-E2不同免疫途径的免疫效力比较[D].泰安:山东农业大学,2014.
[41]夏水利,孙元,雷建林,等.同时接种伪狂犬病活疫苗Bartha-K61株对嵌合载体猪瘟疫苗rAdV-SFV-E2免疫效力的影响[J].中国预防兽医学报,2016, 38(8)6642-645.
[42] Kosmidou A, Ahl N R, Thiel HJ, et al. Differentiation of classical swine fever virus(CSFV)strains using monoclonal antibodies against structural glycoproteins[J]. Veterinary Microbiology, 1995, 47(1-2):111.
[43] Widjojoatnodjo M, Van GH, Van RP, et al. Classical swine fever virus E(rns)deletion mutants:trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines[J]. Journal of Virology, 2000, 74(7):2973-2980.
[44] Hplinka L, Fernandez SI, Prarat M, et al. Development of a live attenuated antigenic marker classical swine fever vaccine[J]. Virology, 20093 384(1):106-113.
[45] Holinka LG, Fernandez SI, Sanford B, et al. Development of an improved live attenuated antigenic marker CSF vaccine strain candidate with an increased genetic stability[J].Virology, 2011(471-473):13-18